A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancer Studie porovnávající kombinaci Trastuzumabu a Capec...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006801-17

A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancer Studie porovnávající kombinaci Trastuzumabu a Capecitabinu podávanou s nebo bez Pertuzumabu u pacientek s HER2 pozitivním metastatickým karcinomem prsu

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare progression-free survival (PFS) between the two treatment arms based on assessments by an independent review facility (IRF).


Critère d'inclusion

  • HER2 positive metastatic breast cancer which has progressed after one line of trastuzumab-based therapy in the metastatic setting